Ackman: Allergan misled investors to sink Valeant's shares; NICE recommends Glivec in GIST; Ranbaxy settles Texas case;

@FiercePharma: Tops in FierceVaccines Thurs: NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. Story | Follow @FiercePharma

@EricPFierce: I suspect Laura Schumacher spent late nights as AbbVie board decided whether to walk away from Shire deal. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. Subscribe here to get it weekly. Subscribe | Follow @CarlyHFierce

> Valeant ($VRX) takeover partner Bill Ackman says his lawyers have documents that show Allergan ($AGN) misled investors to fend off the Canadian pharma's hostile bid. More

> The U.K.'s cost-effectiveness gatekeeper has recommended Novartis' ($NVS) Glivec for up to three years in patients who have had a gastro-intestinal stromal tumor and are at a high risk of recurrence. More

> Ranbaxy Laboratories will pay nearly $40 million to settle a case in Texas saying that it had overpriced drugs to the state Medicaid program. Story

> India's Cadila is recalling 5,400 bottles of its version of the anti-hypertension drug Atenolo because they do not meet specifications. Report

> The government in Egypt has selected 5 drugmakers there to produce generic versions of hep C drug Sovaldi. Story

> Some public interest groups are concerned that patent protections being written into a new Pacific Rim trade pact will delay lower cost generic drugs sales in some poor countries. Story

Medical Device News

@FierceMedDev: Medical device venture deals pull in more money per deal. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: Stryker scores with Q3 earnings, beating the Street's expectations and posting $2.39B in revenue. Article | Follow @EmilyWFierce

@MichaelGFierce: Stealthy, DNA-based 'nano-cocoons' deliver #cancer-killing payloads. News | Follow @MichaelGFierce

> Former GE Healthcare head John Dineen joins private equity group. More

> Stryker to repatriate $2B, ready for acquisitions in 2H15. Story

> Boston Scientific wins CE mark for MRI-friendly pacemaker products. News

Biotech News

@FierceBiotech: Astellas backs out of a $760M Alzheimer's deal with CoMentis. Item | Follow @FierceBiotech

@JohnCFierce: This low-T field is definitely starting to look like the slum area of R&D. | Follow @JohnCFierce

@DamianFierce: Early look at Adaptimmune's cancer immunotherapy data: 1 complete response and 3 partials among 5 patients. Story | Follow @DamianFierce

@EmilyMFierce: The long and ugly tradition of treating Africa as a dirty, diseased place. More | Follow @EmilyMFierce

> Amgen sues to block Sanofi and Regeneron at the PCSK9 goal line. Article

> Repros plummets as the FDA deals a blow to its low-T hopes. Story

> Adaptimmune's novel cancer treatment posts promising early results. More

And Finally... For the third year in a row, Regeneron ($REGN) has topped of Science magazine's top 20 employers survey, followed by Novo Nordisk ($NVO) and Roche's ($RHHBY) Genentech unit. More

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.